✦ LIBER ✦

12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS

✍ Scribed by D.R. Nelson; E. Lawitz; V. Bain; N. Gitlin; T. Hawkins; P. Marotta; K. Workowski; S. Flamm; P.S. Pang; J.G. McHutchison; J. McNally; P. Urbanek; E.M. Yoshida

Book ID: 117380226
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 127 KB
Volume: 56
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(12)60026-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

14 EFFICACY AND SAFETY OF WEIGHT-BASED R

14 EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C

✍ F. Poordad; E. Lawitz; R. Pozza; M. Shiffman; B. Bacon; E. Godofsky; D. Halliman 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

64 GS-5885 + GS-9451 + PEGINTERFERON AND

64 GS-5885 + GS-9451 + PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAÏVE GENOTYPE 1 IL28B CC PATIENTS

✍ Thompson, A.; Han, S.; Shiffman, M.L.; Rossaro, L.; Ghalib, R.; Beavers, K.; Pia 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

448 RESPONSE-GUIDED THERAPY WITH BOCEPRE

448 RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN REDUCES DURATION IN NAIVE AND PEGINTERFERON ALFA-2B/RIBAVIRIN PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV GENOTYPE 1

✍ M.P. Manns; F. Poordad; B.R. Bacon; S. Bruno; R. Esteban; M. Silva; M. Buti; M. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Response-Guided Therapy With Boceprevir

Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Reduces Treatment Duration in NaïVE and Peginterferon Alfa-2B/Ribavirin Previous-Treatment-Failure Patients With HCV Genotype 1

✍ Manns, Michael P. ;Poordad, Fred ;Bacon, Bruce R. ;Bruno, Savino ;Esteban, Rafae 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 258 KB

Clinical trial: exposure to ribavirin pr

Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin

✍ V. G. BAIN; S. S. LEE; K. PELTEKIAN; E. M. YOSHIDA; M. DESCHÊNES; M. SHERMAN; R. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

328 Comparison of 48 or 72 weeks of trea

328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1

✍ Thomas Berg; M. Von Wagner; H. Hinrichsen; T. Heintges; P. Buggisch; T. Goeser; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB